Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: ANXA2R

Gene summary for ANXA2R

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

ANXA2R

Gene ID

389289

Gene nameannexin A2 receptor
Gene AliasAX2R
Cytomap5p12
Gene Typeprotein-coding
GO ID

GO:0003674

UniProtAcc

Q3ZCQ2


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
389289ANXA2RP37T-EHumanEsophagusESCC1.53e-039.86e-020.1371
389289ANXA2RP47T-EHumanEsophagusESCC1.78e-038.40e-020.1067
389289ANXA2RP48T-EHumanEsophagusESCC1.78e-038.23e-020.0959
389289ANXA2RP54T-EHumanEsophagusESCC9.07e-081.72e-010.0975
389289ANXA2RP57T-EHumanEsophagusESCC3.29e-037.47e-020.0926
389289ANXA2RP62T-EHumanEsophagusESCC7.77e-172.75e-010.1302
389289ANXA2RP65T-EHumanEsophagusESCC9.07e-049.54e-020.0978
389289ANXA2RP74T-EHumanEsophagusESCC1.26e-231.00e+000.1479
389289ANXA2RP75T-EHumanEsophagusESCC2.00e-173.81e-010.1125
389289ANXA2RP76T-EHumanEsophagusESCC3.50e-029.33e-020.1207
389289ANXA2RP80T-EHumanEsophagusESCC1.97e-041.39e-010.155
389289ANXA2RP82T-EHumanEsophagusESCC2.98e-073.10e-010.1072
389289ANXA2RP107T-EHumanEsophagusESCC8.98e-037.80e-020.171
389289ANXA2RP127T-EHumanEsophagusESCC1.56e-025.95e-020.0826
389289ANXA2RP128T-EHumanEsophagusESCC5.60e-092.76e-010.1241
389289ANXA2RP130T-EHumanEsophagusESCC4.33e-072.10e-010.1676
389289ANXA2RC30HumanOral cavityOSCC5.50e-126.38e-010.3055
389289ANXA2RC43HumanOral cavityOSCC3.63e-082.35e-010.1704
389289ANXA2RC08HumanOral cavityOSCC5.44e-224.45e-010.1919
389289ANXA2RLP15HumanOral cavityLP8.17e-057.92e-010.2174
Page: 1 2 3 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
ANXA2RSNVMissense_Mutationc.197G>Ap.Gly66Glup.G66EQ3ZCQ2protein_codingtolerated(0.26)benign(0.075)TCGA-EK-A2RJ-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
ANXA2RSNVMissense_Mutationc.121T>Cp.Tyr41Hisp.Y41HQ3ZCQ2protein_codingdeleterious(0)possibly_damaging(0.662)TCGA-CA-6718-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownPD
ANXA2RSNVMissense_Mutationc.371N>Tp.Ser124Ilep.S124IQ3ZCQ2protein_codingtolerated(0.32)benign(0.01)TCGA-AP-A059-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
ANXA2RSNVMissense_Mutationnovelc.293N>Cp.Lys98Thrp.K98TQ3ZCQ2protein_codingtolerated(0.34)possibly_damaging(0.451)TCGA-AX-A06F-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinSD
ANXA2RSNVMissense_Mutationnovelc.275N>Tp.Ser92Ilep.S92IQ3ZCQ2protein_codingtolerated(0.42)benign(0.01)TCGA-AX-A1CF-01Endometriumuterine corpus endometrioid carcinomaFemale>=65III/IVHormone TherapytamoxifenPD
ANXA2RSNVMissense_Mutationnovelc.103C>Tp.Pro35Serp.P35SQ3ZCQ2protein_codingdeleterious(0.04)possibly_damaging(0.737)TCGA-EO-A22U-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
ANXA2RSNVMissense_Mutationnovelc.40N>Ap.Asp14Asnp.D14NQ3ZCQ2protein_codingtolerated(0.27)benign(0.32)TCGA-FI-A2D5-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinumPD
ANXA2RSNVMissense_Mutationnovelc.104N>Gp.Pro35Argp.P35RQ3ZCQ2protein_codingtolerated(0.09)possibly_damaging(0.597)TCGA-DD-AACP-01Liverliver hepatocellular carcinomaMale<65I/IIUnknownUnknownSD
ANXA2RSNVMissense_Mutationnovelc.143C>Tp.Ser48Leup.S48LQ3ZCQ2protein_codingtolerated(0.08)benign(0.204)TCGA-MP-A4TI-01Lunglung adenocarcinomaMale>=65I/IIUnknownUnknownPD
ANXA2RSNVMissense_Mutationrs754645658c.514N>Tp.Val172Phep.V172FQ3ZCQ2protein_codingdeleterious_low_confidence(0.03)possibly_damaging(0.859)TCGA-NJ-A4YQ-01Lunglung adenocarcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1